GRAFT POLYMER

COMBINE INCOMPATIBLE

Investor Update

September 2022

PROGRESS TO DATE

Graft Polymer has already delivered on several **Key Company Milestones** from its IPO in January 2022:

- Achieving cashflow positive at the production plant in Slovenia through organic growth alone
- First US market commercial purchase order for GraftBio division from MGC Pharma
- Switched to two-shift operation at the Slovenia production facility to ensure demand is met
- HAACP certificate enabling access to the B2C market
- Ordering bespoke production equipment that will double GPL's compounding capacities at a lower than budgeted price at IPO
- Granting of seven new patents that were in progress pre-IPO
- Two diverse polymer divisions focusing on increasing the profitability of GPL
- New Bio Supplement Pipeline

GLOBAL PROBLEM AND MARKET CHALLENGES

An increase in global demand for polymer materials, driven by the cost, higher performance and environmental advantages could be satisfied by 2 solutions:

- synthesis of new polymers
- modification of the known polymers (hybrid)

Market challenges in the field of composite materials

- Weight reduction of the product
- Decreasing the cost of the product
- A synergy of the best properties of composite components
- Environmentally responsible production process of the composite material
- Industrial scalability of modification technologies
- Increasing durability and recyclability of the product to increase lifespan and reduce plastic waste

GRAFT POLYMER – BACKGROUND

Graft Polymer Plc (LSE: GPL) is a UK-incorporated company, with dedicated polymer research and manufacturing facilities based in Slovenia.

- Our core business is Polymer Modification. Polymer modification is KEY to creating cutting-edge, polymer composite materials.

- Graft Polymer has two main divisions:

  1. POLYMER DIVISION (Polymer Modification for industrial application) ;
  2. PHARMA/BIO DIVISION (Drug Delivery Systems Developments and Bio Supplements manufacturing based on "GraftBio" DDS platforms)

- Our motto is "combine incompatible" which summarises the core of GPL's business, namely: the use of a diverse range of modification technologies to combine incompatible components into polymer composites.

- GPL is an ESG focused and compliant company, which produces a special ECO line of compatibilisers (based on industrial clean scrap) for recyclers clients.

BOARD PROFILES & CORPORATE INFORMATION

Share price

14.50 GBX*

Market Cap

15.51 (£m)*

Shares in issue

104,097,299*

Ticker

GPL

*as of 13 September 2022

Substantial shareholders*

Name	Number of ordinary shares	Percentage of ordinary shares
Victor Bolduev	30,454,612	29.26
Alba Capital Limited	13,935,020	13.39
Roby Zomer**	6,326,510	6.08
Platypus Assets Pty Ltd	6,250,000	6.00
Premier Miton	6,050,000	5.81

**Roby Zomer holds these shares in an entity called Chitta Lu in which he has a beneficial ownership

Victor Bolduev

Founder & Managing Director

Mr Bolduev is a globally renowned chemist and founder of the Group with over 20 years of international polymer industry experience, particularly in Polymer Modification.

Roby Zomer

Non-Executive Chairman

Mr Zomer is an entrepreneur with +10 years' experience in the biotech and renewable energy sectors. Mr Zomer led Israeli regulation for Alternative Energy and is currently Managing Director of MGC Pharmaceuticals, (LSE/ASX:MXC).

Yifat Steuer

Executive Director & CFO

Ms. Steuer is a well-versed CFO with 20+ years' experience with a proven track record in pharmaceuticals, manufacturing, logistics, medical technology, and digital health industries. Ms. Steuer is a qualified chartered accountant with Deloitte.

Pavel Kobzev

Executive Director & CMO

Mr Kobzev has more than 10 years of experience in project management and market analysis. Mr Kobzev has expertise in the security solutions and design industries and has been managing GPL's client base for five years.

Alex Brooks

Independent Non-Executive Director

Mr Brooks is a financial analyst, currently with Canaccord Genuity Ltd (UK), who focusses on publicly traded industrial technology companies in a number of sectors, notably energy, healthcare and chemicals.

KEY MILESTONES TIMELINE 2022-23

January 2022
- Successful IPO on the London Stock Exchange.

May 2022
- Granting of HACCP certificate enabling access to the B2C market.

June 2022
- The Group’s Slovenian operation reached cash flow positive status through organic growth alone.

Q3 2022
- First US market commercial purchase order for GraftBio division from MGC Pharma

Q4 2022
- Install and commissioning our bespoke product line and GraftBio facility

Q1 2023
- New revenue driving contracts with new and existing customers

Q2 2023
- Enhancing our IP strategy with further patents

POLYMER MODIFICATION – PRODUCTS

The Group also has an **extensive IP and patent strategy** and holds several patents for its drug delivery systems.

GPL has a range of innovative products that offer key advantages over its competition:

- Our GRAFTASYNT HFFR product is a flame-retardant liquid additive and is effective at low dosage.
- GRAFTAMER VTR, creates a cost-effective commercial method of manufacturing VITRIMERS, a novel class of polymers which effectively combine the attractive features of both thermoset and thermoplastic polymers, on the base of a low-cost thermoplastic, creating a finished blend that is mechanically strong and solvent resistant, which can be thermoformed, and which can be readily recycled.
- With GRAFTAPOR customers can blend immiscible additives into a polymeric compound and guarantee a superior control of additives during the manufacturing process.

Many polymers are **immiscible** and **incompatible** by nature. **Polymer modification can solve this problem** and makes it possible to develop **new composite materials** with a unique combination of physical and chemical features:

- Impact resistant
- Fire retardant
- Low/High temperature resistant
- Abrasive resistant
- Chemical resistant
- Barrier property and etc.
- “Smart” Polymers: with Self-Healing properties
- Proprietary Initiating Systems allow us to produce the most sophisticated Graft Polymer Modifiers currently known in the Polymer industry

POLYMER BUSINESS MODEL: COMPREHENSIVE & INNOVATIVE

TECHNOLOGIES	GRAFT POLYMER Slovenia	Polyram Israel	AUSER POLIMERI Italy	BYK Germany	ExxonMobil USA	Dow DUPONT	ARKEMA France	SILON Czech	PLUSS India	佳易容 Fine-Blend China
Flow induced crystallization	✔									
Solid Phase Grafting	✔			✔						
Solution Grafting	✔				✔	✔	✔			✔
Fillers Treatments	✔									
Powders Hybridization	✔						✔			
Hot ozonolysis/plasma mod.	✔									
Nitroxide Mediated Polymerization	✔						✔			
Reactive extrusion	✔	✔	✔	✔	✔	✔	✔	✔	✔	✔
Alloying	✔	✔				✔	✔		✔	
Crosslinking	✔					✔		✔		
Micro/Nano Porous polymer	✔									

GRAFT POLYMER'S GREEN CREDENTIALS

- Environment, Social and Governance the facility in Slovenia has been granted ISO 14001 accreditation in recognition of the environmental management systems in place to reduce waste.
- Clean recycling scrap matrix GPL is using clean scrap raw materials during the production of "ECO LINE" modifiers.
- Closed system loop - modern processing techniques are used to minimise waste almost to zero.
- We only use environmental REACH/ROHS certificated raw materials in our process.
- GPL's extensive R&D programme has developed specialised recycling polymer additives which increases the strength of recycled blends and plastic products whilst also reducing plastic waste by between 40 and 50 per cent.
- GPL uses specialised recycling polymer additives that increase the strength of recycled blends.
- Our Proprietary co-agents and redox initiating system are used during the grafting process which improves the efficiency of our Drug Delivery systems and allows a decrease in the dosage by 50% to the end client

POLYMERS BUSINESS MODEL: STRUCTURE AND FEATURES

- Comprehensive
- Innovative
- Flexible

GRAFTING

GRAFTABOND™
a line of *graft/block copolymers* (adhesive agents) for combining various polymers.

GRAFTAKIT™
reaction liquid *super concentrates* on *polymeric porous* media for carrying out reaction extrusion and modification of compounds directly “at the customer’s production line”.





ALLOYING

GRAFTALLOY™
a line of “*polymer-polymer*" *nano-alloys* to increase abrasion resistance, temperature resistance, impact strength, reduce friction coefficient.

GRAFTAMID™
a line of high-temperature elastomers based on *nanostructured polyolefin-polyamide alloys* for high-tech hardening modifiers in polyamide compounds.



CROSSLINKING

GRAFTAMER™
unique so-called “smart polymers” (*thermally reversible* cross-linking, *self-hardening, self-healing*, polymers with “shape memory”).

GRAFTAKIT™
reaction liquid *super concentrates* on *polymeric porous* media for carrying out reaction extrusion and modification of compounds directly “at the customer’s production line”.

SYNTHESIS

GRAFTASYNT™
a line of *synthetic* products, including HFFR flame retardants (*halogen-free*).

POROUS

GRAFTAPOR™
a unique line of *porous* (80-120% porosity) polymer *carriers* for many liquid chemicals absorption.

BIO BUSINESS MODEL: STRUCTURE

DDS | Micro & Nano capsulation

Graft Polymer Slovenia is currently conducting research on smart nanostructured materials to deliver drugs to target sites with reduced dosage frequency and in a controlled manner, to mitigate the side effects experienced with traditional treatments.

GPL Drug Delivery Platforms
GraftBio™

- Nano-micellar
  - *GraftBio™ SNEDDS Nano-emulsion plarform for various API*
- Nano-capsule
  - *Grafted PCL nano particles (solvent evaporation - W/O emulsion method)*
- Porous nano-reservoir
  - *SYNTETIC biodegradable porous reservoir*
  - *NATURAL organic biodegradable porous reservoir*
- Bio-gel
  - *Bio-material for substitution of human tissue*
- Dendrimers
  - *Hyper Branched Polymers*






GRAFTBIO™
Bio Synthesis (a bio synthesis site) for Drug Delivery Systems (DDS) developments

GPL has food GMP production facilities following the granting of an HAACP certificate

MARKETS VOLUMES & TARGET MARKET

The global Hot Melt Adhesives market was valued at **US$ 7.1 billion in 2022** and is estimated to reach US$10.10 billion by 2029.

The global PP nonwoven fabrics market was estimated at **US$ 40.5 billion in 2020** and is expected to reach US$ 53.5 billion by 2025

The global DDS market was **USD$ 39.33 billion in 2021** and is projected to reach US$ 71.75 billion by 2029.

The HFFR market was estimated at **US$ 4.1 billion in 2020** and is expected to grow at a CAGR of 8.60% reaching US$ 6.2 billion by 2025

Hot Melts

- Compatibilizers
- Grafted wax
- Adhesion enhancement
- Thermal properties enhancement

Non-Woven

- Super Hydrophilic MB
- Super Hydrophobic MB
- Melt-Flow regulator PP nonwovens
- Reactive MB for High Melt Strength Polypropylene

Recycling

- Compatibilizers for mixed colour and polyolefin scrap
- Compatibilizers for blow moulding
- Melt Flow regulator for PP
- Melt Flow enhancer for PE

Pharmaceutical

- Nanocarriers for Drug Delivery System
- Supplements for medical uses such as Covid-19

DISTRIBUTION NETWORK AND MAP

Model focused on maximising distribution/sales and market visibility globally

EU based offering key advantages:

- Already adheres to EU laws and regulations allowing easy sales and distribution to other EU companies and worldwide
- Extensive EU recycling programme GPL can take advantage of with its "ECO Line" modifiers
- Strong IP laws keep GPL's proprietary knowledge protected

Distribution Partners

- Bedeko (Poland)
- Bharat Enterprises (India)
- Vilher (Mexico)
- Ersbloh GmbH (Europe)
- Lehmann&Voss&Co. (Europe)
- Ferro-Plast Srl (Italy)
- Savanture LLC (USA)
- Pronativetrader (Thailand)
- JSB (Turkey)
- Technical polymers consultancy & Trading (Belgium)



Active agents / companies

In progress with potential distributers

EU PRODUCTION FACILITY – UPGRADE UNDERWAY

- Cutting edge +1,000m^2 production and R&D facility and a 2nd production line installed
- New bio operations facility installation
- Research, develop and test various combinations of polymer solutions
- Production capacity of up to 4,500 tons of product per annum
- Able to produce multiple products and ship to clients on demand
- Collaboration with the Faculty of Polymer Technology (FTPO Slovenia)

KEY ACHIEVEMENTS

A strong start to listing with a steady positive news flow and cashflow positive news flow

- Successfully raised £5m in IPO, currently with £2m net cash in the bank after CAPEX spend
- ESG compliant with a focus on utilising recycled products and improving production to reduce waste
- New production line and bio facility to double output. Q3/Q4 operational
- Highly experienced research and production team to run the facility at optimal levels and develop new products
- Cashflow positive operations through organic growth alone
- Focused on delivering new material for revenue-driving contracts for the next 6-12 months
- New customer pipeline, GPL is continually expanding its customer base whilst maintain existing customer relationships

Disclaimer

This presentation and any additional documents handed out at any meeting or provided directly to potential investors (together the "Presentation Materials") have not been approved by: (i)) the London Stock Exchange plc or by any authority which could be a competent authority for the purposes of the Prospectus Directive (Directive 2003/71/EC); or (ii) an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). The securities mentioned herein have not been and will not be, registered under the US. Securities Act of 1933, as amended (the "Securities Act"), or under any US. State securities laws, and may not be offered or sold in the United States unless they are registered under the Securities Act or pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act. Neither the US. Securities and Exchange Commission nor any US. state regulatory authority has approved the securities to be offered or the terms of such of fering or passed upon the accuracy or adequacy of the presentation and these Presentation Materials. Any representation to the contrary is a criminal offence.

The Presentation Materials are being supplied to you for information purposes only by Graft Polymer plc (the "Company"). References to the Company will also be deemed to include its subsidiaries (if any), both directly and indirectly held (including through nominees) all or wholly owned. These Presentation Materials have been prepared by and are the sole responsibility of the Company. The Directors of the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief. Inve sting in the Company may expose an individual to significant risk of losing all of the property or other assets invested.

These Presentation Materials, being this presentation and any additional documents handed out in the meeting or provided directly to potential investors, are being issued on a strictly private and confidential basis and solely to and directed (i) at persons in the UK (a) who have professional experience in matters relating to investments, being investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO"), (b) high net worth companies as defined in Article 49(2) of the FPO, (c) certified sophisticated investors as defined in Article 50(1) of the FPO or (d) persons to whom it may otherwise lawfully be communicated or (ii) persons in the United States or who are US. persons, who are "accredited investor s" as defined in Rule 501 of Regulation D promulgated under the Securities Act ("Accredited Investors") (together "Relevant Persons"). In order to qualify as a certified sophisticated investor you must have a current certificate signed by a person authorised by the Financial Conduct Authority to the effect that you are sufficiently knowledgeable to understand the risks associated with this particular type of investment and you must have signed within the last 12 months a statement in the terms set out in Article 50(1)

Any recipient of these Presentation Materials who is in any doubt about the investment to which this presentation relates should consult an authorised person specialising in advising on investments of this kind. These Presentation Materials do not constitute a recommendation regarding the shares of the Company, and should not be construed as le gal, business, tax or investment advice. Prospective investors are encouraged to obtain separate and independent verification of information and opinions contained in the Presentation Materials as part of their ow n due diligence. By accepting these Presentation Materials, the Recipient agrees to keep permanently confidential the information contained herein or sent herewith or made available in connection with further enquiries. It is a condition of the issue of these Presentation Materials that they will not be reproduced, copied, distributed or circulated to any third party, in whole

or in part, or published in whole or in part for any purpose, without the express prior consent of the Company. Neither the Company, nor its advisers accept liability whatsoever for any loss howsoever arising, directly or indirectly, from use of these Presentation Materials or their contents or otherwise arising in connection therewith. The Company, in its sole discretion, reserves the right to amend or supplement these Presentation Materials at any time. The

Company also reserves the right, in its sole discretion, to terminate discussions with any person at any time. The reproduction, copying or distribution of these Presentation Materials in other jurisdictions may be restricted by law and persons into whose possession these Presentation Materials come should inform themselves about, and observe, any such restrictions. These Presentation Materials are not for distribution outside the United Kingdom (other than to the

These Presentation Materials do not constitute, or form part of, a prospectus or admission document relating to the Company, nor do they constitute or contain any invitation or offer to any person to subscribe for, purchase or otherwise acquire any shares in the Company or advise persons to do so in any jurisdiction, nor shall it, or any part of it form the basis of or be relied on in connection with any contract or as any inducement to enter into a contract or commitment with the Company. No reliance may be placed for any purpose whatsoever on the information or opinions contained in the Presentation Materials or on their completeness. No representation or warranty, express or implied, is given by the Company as to the accuracy of the information or opinions contained in the Presentation Materials, or any further written or oral information made available to you or your advisors, and is subject to updating, completion, revision, amendment or verification, which may result in material changes.

(b) of the FPO. The ordinary shares are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire the ordinary shares will be engaged in only with, Relevant Persons. Any person who is not a Relevant Person should not rely on this document nor take any action upon it, but should return it immediately to the Company.

United States in certain circumstances) and in particular, they or any copy of them should not be distributed, directly or indirectly, by any means (including electronic transmission) either to persons with addresses in Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland, or to any citizens, nationals or residents thereof, or to any corporation, partnership or other entity created or organized under the laws thereof. Any failure to comply with these restrictions may constitute a violation of the laws of any such other jurisdictions.

These Presentation Materials contain certain forward looking information about the Company which are statements, beliefs, opinions or projections that are not historical facts, and which may be identified by the use of terminology such as "proposes," "may," "believes," "anticipates," "projects," "expects," estimates" or "forecasts" or comparable terminology and which reflect the Company's or, as appropriate, the Company's Directors current expectations and beliefs about future events. By their nature, forward looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed in such statements, beliefs and opinions depending on a variety of factors. Past performance, trends or activities of the Company or its shares cannot be relied

on as a guide to future performance, trends or activities. Any forward looking information contained in these Presentation Materials has been prepared on the basis of a number of assumptions which may prove to be incorrect, and accordingly, actual results may vary from those projected as a result of, among other factors, changes in economic and market conditions, changes in the regulatory environment and other business and operational risks. Recipients of these Presentation Materials should not place reliance on forward looking statements, which speak only as of the date of the Presentation Materials. The Comp any does not undertake

any obligation to update or revise any forward looking statements, whether as a result of new information, future events, circumstances or otherwise or to reflect the occurrence or non occurrence of any events.

Please note that the photographs and images used in these Presentation Materials are illustrative and may not show a complete picture of all relevant information. By attending the presentation and/or retaining these Presentation Materials you will be taken to have represented, warranted and undertaken that: (i) you a re a Relevant Person (ii) you have read and agree to comply with the contents and restrictions of this disclaimer (iii) you will use the information in these Presentation Materials solely for evaluating your possible interest in acquiring securities of the Company and (iv) you will conduct your own analysis or other verification of the data and information set out in these Presentation Materials and will bear the responsibility for all or any costs incurred in doing so.

GRAFT POLYMER
COMBINE INCOMPATIBLE

THANK YOU

CONTACT INFO

Pavel Kobzev
Executive Director & CMO
Phone: +386 40 867 937
Pavel@graftpolymer.com

St Brides Partners
PR Agency
Graftpolymer@stbridespartners.co.uk

Turner Pope
Broker
First-insiders@turnerpope.com

www.graftpolymer.com Info@graftpolymer.com